Cipla Sets Ambitious $1 Billion US Run-Rate Target, Eyes 18.5-20% EBITDA Margin for Fiscal 2027

Cipla Guides for $1 Billion US Revenue by End of FY27

Indian pharmaceutical major Cipla has provided guidance for a $1 billion annualised run-rate in the US by the end of FY27, while maintaining operating discipline. The guidance comes despite a decline in generic Revlimid (lenalidomide) sales and lanreotide supply disruptions.

Cipla, with its US business at $780 million in FY26, is banking on the commercialisation of generic Ventolin (albuterol inhaler) in the US, expected to be launched in FY27. The company aims to achieve EBITDA margins of 18.5 percent to 20 percent for FY27, with sequential improvement through the year driven by new launches and operating leverage.

The guidance comes after a weak March quarter, where Cipla reported Q4FY26 revenue of Rs.6,541 crore, EBITDA of Rs.997 crore, and net profit of Rs.555 crore, reflecting a sharp decline from the previous year. For the full year, revenue stood at Rs.28,163 crore, while EBITDA was Rs.5,925 crore and net profit Rs.3,879 crore. The company ended the year with a strong net cash position of about ₹10,526 crore, providing flexibility for future investments.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Key Performance Indicators (KPIs)

Achin Gupta, Managing Director and Global CEO, attributed the earnings pressure to a mix of factors, including increased R&D spending, higher manufacturing costs in the US, and the absence of certain high-margin products. The company has continued to invest in R&D and scaled up US facilities, with these investments expected to support growth in coming quarters.

The US, which has faced headwinds from product-specific issues such as lenalidomide, is poised for recovery through a strong pipeline. Cipla is banking on a sequence of launches, including respiratory products and complex generics, to rebuild momentum. Beyond the US, the company remains confident about its core markets, with India expected to deliver double-digit growth, supported by strong traction across prescription, trade generics, and consumer health segments.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

However, Cipla is navigating external challenges such as supply chain disruptions and rising input costs. While geopolitical tensions have had a limited impact so far, Gupta cautioned that the costs of these disruptions could seep into the company's system if they persist, potentially leading to margin pressures.

Despite these challenges, Cipla expects both revenue and profitability to recover progressively through FY27, with investments in R&D, manufacturing, and new product pipelines already underway.